newsfilter
← Latest News
GlobeNewswire·

4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones

UPCDCOYVRDN
  • Universe Pharmaceuticals (NASDAQ: UPC) agreed to acquire Best Praise International Limited in an all-stock deal valued at approximately $10.75 million to add five China-based pharmaceutical patents.
  • The acquisition is expected to close in Q3 2026 after customary conditions are met, aiming to strengthen R&D in therapeutic areas like neurodegenerative disorders & drug delivery.
  • NeOnc Technologies (NASDAQ: NTHI) received a second Investigational New Drug (IND) authorization from Abu Dhabi for its lead candidate NEO100 in recurrent high-grade gliomas.
  • The new authorization covers adult Phase 1 & 2 studies as well as a pediatric pathway, complementing the earlier UAE authorization for NEO212.
  • NeOnc expects top-line Phase 2a data for NEO100-01 by the end of July, while NEO100 holds FDA Orphan Drug, Fast Track, & Rare Pediatric Disease designations.
  • NeOnc Chairman, President, & CEO Amir Heshmatpour invested over $500,000 personally, bringing total insider purchases to nearly $1 million in the past year.
  • NeOnc has access to a $75 million at-the-market facility & a $10 million line of credit, with institutional holders including Bank of America, State Street, & Barclays.
  • Decoy Therapeutics (NASDAQ: DCOY) announced a private placement financing that could yield up to $21 million through upfront proceeds & milestone-based warrant exercises.
  • The initial Decoy closing is projected to generate approximately $3.5 million, with additional funding tied to European trial authorization, UK Phase 2a approval, & positive challenge trial data.
  • Viridian Therapeutics (NASDAQ: VRDN) received FDA approval for Lumvoa™ (veligrotug-vvze), its first commercial product for thyroid eye disease.
  • Lumvoa is the first therapy for this condition with labeling covering both active & chronic disease, supported by two Phase 3 trials meeting primary & secondary endpoints.
  • Viridian plans an immediate commercial launch of Lumvoa & a subcutaneous candidate elegrobart, targeting a Biologics License Application submission in Q1 2027.
  • Viridian introduced the ViridianCares™ patient support program to assist with patient access following commercialization.